Differential effects of S100 proteins A2 and A6 on cardiac Ca2+ cycling and contractile performance

Journal of Molecular and Cellular Cardiology

Volumn 72, Issue , 2014, Pages 117-125

  Wang, Wang ^a,b   Asp, Michelle L ^a   Guerrero Serna, Guadalupe ^a,c   Metzger, Joseph M ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Cardiac calcium handling; Excitation contraction coupling; Gene therapy; Heart failure; S100 proteins

Indexed keywords

CALCIUM BINDING PROTEIN; CALCYCLIN; PROTEIN S 100 A1; PROTEIN S 100 A2; RYANODINE RECEPTOR; UNCLASSIFIED DRUG; CALCIUM; CELL CYCLE PROTEIN; CHEMOTACTIC FACTOR; PROTEIN S 100; S100A2 PROTEIN, HUMAN; S100A6 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM CELL LEVEL; CONTROLLED STUDY; DOG; GENE EXPRESSION; GENE TRANSFER; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE RELAXATION; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; RAT; RODENT; SEQUENCE HOMOLOGY; ADENOVIRIDAE; ANIMAL; GENE EXPRESSION REGULATION; GENE VECTOR; GENETICS; HEART CONTRACTION; HEART VENTRICLE; HUMAN; ION TRANSPORT; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PRIMARY CELL CULTURE; SPRAGUE DAWLEY RAT;

ADENOVIRIDAE; ANIMALS; CALCIUM; CELL CYCLE PROTEINS; CHEMOTACTIC FACTORS; DOGS; GENE EXPRESSION REGULATION; GENETIC VECTORS; HEART FAILURE; HEART VENTRICLES; HUMANS; ION TRANSPORT; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; PRIMARY CELL CULTURE; RATS; RATS, SPRAGUE-DAWLEY; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; S100 PROTEINS;

EID: 84901304987     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2014.03.003     Document Type: Article

References (50)

1. Lloyd-Jones D., Adams R., Carnethon M., De Simone G., Ferguson T.B., Flegal K., et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009, 119:e21-e181.
2. 2+ cycling and new therapeutic approaches for heart failure. Circulation 2010, 121:822-830.
3. Birkeland J.A., Sejersted O.M., Taraldsen T., Sjaastad I. EC-coupling in normal and failing hearts. Scand Cardiovasc J 2005, 39:13-23.
4. 2+ handling in heart failure. J Clin Invest 2005, 115:556-564.
5. Koitabashi N., Kass D.A. Reverse remodeling in heart failure-mechanisms and therapeutic opportunities. Nat Rev Cardiol 2012, 9:147-157.
6. 2+ cycling as a key pathogenic mechanism of heart failure. Circ J 2008, 72(Suppl. A):A22-A30.
7. Tomaselli G.F., Marban E. Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res 1999, 42:270-283.
8. Hasenfuss G., Pieske B. Calcium cycling in congestive heart failure. J Mol Cell Cardiol 2002, 34:951-969.
9. Piacentino V., Weber C.R., Chen X., Weisser-Thomas J., Margulies K.B., Bers D.M., et al. Cellular basis of abnormal calcium transients of failing human ventricular myocytes. Circ Res 2003, 92:651-658.
10. Hulot J.S., Senyei G., Hajjar R.J. Sarcoplasmic reticulum and calcium cycling targeting by gene therapy. Gene Ther 2012, 19:596-599.
11. Wehrens X.H., Marks A.R. Novel therapeutic approaches for heart failure by normalizing calcium cycling. Nat Rev Drug Discov 2004, 3:565-573.
12. Ritterhoff J., Most P. Targeting S100A1 in heart failure. Gene Ther 2012, 19:613-621.
13. Heizmann C.W., Fritz G., Schafer B.W. S100 proteins: structure, functions and pathology. Front Biosci 2002, 7:d1356-d1368.
14. Heizmann C.W. The multifunctional S100 protein family. Methods Mol Biol 2002, 172:69-80.
15. Salama I., Malone P.S., Mihaimeed F., Jones J.L. A review of the S100 proteins in cancer. Eur J Surg Oncol 2008, 34:357-364.
16. Chan W.Y., Xia C.L., Dong D.C., Heizmann C.W., Yew D.T. Differential expression of S100 proteins in the developing human hippocampus and temporal cortex. Microsc Res Tech 2003, 60:600-613.
17. Buckiova D., Syka J. Calbindin and S100 protein expression in the developing inner ear in mice. J Comp Neurol 2009, 513:469-482.
18. Zimmer D.B., Wright Sadosky P., Weber D.J. Molecular mechanisms of S100-target protein interactions. Microsc Res Tech 2003, 60:552-559.
19. Kraus C., Rohde D., Weidenhammer C., Qiu G., Pleger S.T., Voelkers M., et al. S100A1 in cardiovascular health and disease: closing the gap between basic science and clinical therapy. J Mol Cell Cardiol 2009, 47:445-455.
20. Davis J., Westfall M.V., Townsend D., Blankinship M., Herron T.J., Guerrero-Serna G., et al. Designing heart performance by gene transfer. Physiol Rev 2008, 88:1567-1651.
21. 2+ handling, sarcomeric, and mitochondrial function. J Biomed Biotechnol 2010, 2010:178614.
22. Wright N.T., Cannon B.R., Zimmer D.B., Weber D.J. S100A1: structure, function, and therapeutic potential. Curr Chem Biol 2009, 3:138-145.
23. Most P., Pleger S.T., Volkers M., Heidt B., Boerries M., Weichenhan D., et al. Cardiac adenoviral S100A1 gene delivery rescues failing myocardium. J Clin Invest 2004, 114:1550-1563.
24. Pleger S.T., Most P., Boucher M., Soltys S., Chuprun J.K., Pleger W., et al. Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue. Circulation 2007, 115:2506-2515.
25. Glenney J.R., Kindy M.S., Zokas L. Isolation of a new member of the S100 protein family: amino acid sequence, tissue, and subcellular distribution. J Cell Biol 1989, 108:569-578.
26. Schaub M.C., Heizmann C.W. Calcium, troponin, calmodulin, S100 proteins: from myocardial basics to new therapeutic strategies. Biochem Biophys Res Commun 2008, 369:247-264.
27. Engelkamp D., Schafer B.W., Erne P., Heizmann C.W. S100 alpha, CAPL, and CACY: molecular cloning and expression analysis of three calcium-binding proteins from human heart. Biochemistry 1992, 31:10258-10264.
28. Lesniak W., Slomnicki L.P., Filipek A. S100A6 - new facts and features. Biochem Biophys Res Commun 2009, 390:1087-1092.
29. Westfall M.V., Rust E.M., Albayya F., Metzger J.M. Adenovirus-mediated myofilament gene transfer into adult cardiac myocytes. Methods Cell Biol 1997, 52:307-322.
30. 2+-activated tension in adenovirus infected adult cardiac myocytes. Mol Cell Biochem 1998, 181:143-155.
31. Coutu P., Metzger J.M. Optimal range for parvalbumin as relaxing agent in adult cardiac myocytes: gene transfer and mathematical modeling. Biophys J 2002, 82:2565-2579.
32. Townsend D., Turner I., Yasuda S., Martindale J., Davis J., Shillingford M., et al. Chronic administration of membrane sealant prevents severe cardiac injury and ventricular dilatation in dystrophic dogs. J Clin Invest 2010, 120:1140-1150.
33. Coutu P., Metzger J.M. Genetic manipulation of calcium-handling proteins in cardiac myocytes. I. Experimental studies. Am J Physiol Heart Circ Physiol 2005, 288:H601-H612.
34. Herron T.J., Vandenboom R., Fomicheva E., Mundada L., Edwards T., Metzger J.M. Calcium-independent negative inotropy by beta-myosin heavy chain gene transfer in cardiac myocytes. Circ Res 2007, 100:1182-1190.
35. 2+ cycling. Circ Res 2007, 100:96-104.
36. Fomicheva E.V., Turner I.I., Edwards T.G., Hoff J., Arden E., D'Alecy L.G., et al. Double oxygen-sensing vector system for robust hypoxia/ischemia-regulated gene induction in cardiac muscle in vitro and in vivo. Mol Ther 2008, 16:1594-1601.
37. 2+ cycling in rat cardiac myocytes. Basic Res Cardiol 2002, 97(Suppl. 1):I56-I62.
38. Kettlewell S., Most P., Currie S., Koch W.J., Smith G.L. S100A1 increases the gain of excitation-contraction coupling in isolated rabbit ventricular cardiomyocytes. J Mol Cell Cardiol 2005, 39:900-910.
39. 2+-cycling in ventricular rat cardiomyocytes. J Cell Sci 2005, 118:421-431.
40. 2+ exchange current in the normal and failing heart. Ann N Y Acad Sci 2007, 1099:361-372.
41. Bers D.M. Cardiac excitation-contraction coupling. Nature 2002, 415:198-205.
42. Most P., Bernotat J., Ehlermann P., Pleger S.T., Reppel M., Borries M., et al. S100A1: a regulator of myocardial contractility. Proc Natl Acad Sci U S A 2001, 98:13889-13894.
43. Wolf S., Haase-Kohn C., Pietzsch J. S100A2 in cancerogenesis: a friend or a foe?. Amino Acids 2011, 41:849-861.
44. 2+-binding protein S100A1 in human cardiomyopathy. Biochim Biophys Acta 1996, 1313:253-257.
45. Remppis A., Pleger S.T., Most P., Lindenkamp J., Ehlermann P., Schweda C., et al. S100A1 gene transfer: a strategy to strengthen engineered cardiac grafts. J Gene Med 2004, 6:387-394.
46. Marenholz I., Heizmann C.W., Fritz G. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun 2004, 322:1111-1122.
47. 2+-free S100A2 at 1.6-A resolution. J Mol Biol 2008, 378:933-942.
48. 2+-binding protein family. Biometals 1998, 11:383-397.
49. 2+-loaded S100A2 at 1.3-A resolution. FEBS J 2012, 279:1799-1810.
50. 2+-dependent interaction of S100A1 with F1-ATPase leads to an increased ATP content in cardiomyocytes. Mol Cell Biol 2007, 27:4365-4373.